Medscape is available in 5 Language Editions – Choose your Edition here.


Hypertrophic Cardiomyopathy

  • Author: Sandy N Shah, DO, MBA, FACC, FACP, FACOI; Chief Editor: Henry H Ooi, MD, MRCPI  more...
Updated: Jan 05, 2016

Practice Essentials

Hypertrophic cardiomyopathy (HCM) is a genetic cardiovascular disease. It is defined by an increase in left ventricular wall thickness that is not solely explained by abnormal loading conditions. This disorder is caused by a mutation in cardiac sarcomere protein genes and is most frequently transmitted as an autosomal dominant trait. HCM has a variable presentation.

Signs and symptoms

Signs and symptoms of HCM can include the following:

  • Sudden cardiac death (the most devastating presenting manifestation)
  • Dyspnea (the most common presenting symptom)
  • Syncope and presyncope
  • Angina
  • Palpitations
  • Orthopnea and paroxysmal nocturnal dyspnea (early signs of congestive heart failure [CHF])
  • CHF (relatively uncommon but sometimes seen)
  • Dizziness

Physical findings may include the following:

  • Double apical impulse or triple apical impulse (less common)
  • Normal first heart sound; second heart sound usually is normally split but is paradoxically split in some patients with severe outflow gradients; S3 gallop is common in children but signifies decompensated CHF in adults; S4 is frequently heard
  • Jugular venous pulse revealing a prominent a wave
  • Double carotid arterial pulse
  • Apical precordial impulse that is displaced laterally and usually is abnormally forceful and enlarged
  • Systolic ejection crescendo-decrescendo murmur
  • Holosystolic murmur at the apex and axilla of mitral regurgitation
  • Diastolic decrescendo murmur of aortic regurgitation (10% of patients)

See Clinical Presentation for more detail.


No specific laboratory blood tests are required in the workup. Genetic testing is not yet widely available but is becoming increasingly so.

Two-dimensional (2-D) echocardiography may be diagnostic for HCM. Findings may be summarized as follows:

  • Abnormal systolic anterior leaflet motion of the mitral valve
  • Left ventricular hypertrophy (LVH)
  • Left atrial enlargement
  • Small ventricular chamber size
  • Septal hypertrophy with septal-to-free wall ratio greater than 1.4:1
  • Mitral valve prolapse and mitral regurgitation
  • Decreased midaortic flow
  • Partial systolic closure of the aortic valve in midsystole

Other imaging modalities that may be useful include the following:

  • Chest radiography
  • Radionuclide imaging
  • Cardiac magnetic resonance imaging: Particularly useful when echocardiography is questionable, particularly with apical hypertrophy

Electrocardiographic findings may include the following:

  • ST-T wave abnormalities and LVH (common)
  • Axis deviation (right or left)
  • Conduction abnormalities (P-R prolongation, bundle-branch block)
  • Sinus bradycardia with ectopic atrial rhythm
  • Atrial enlargement
  • Abnormal and prominent Q wave in the anterior precordial and lateral limb leads, short P-R interval with QRS suggestive of preexcitation, atrial fibrillation (poor prognostic sign), and a P-wave abnormality (all uncommon)

The following diagnostic modalities may also be useful:

  • Cardiac catheterization (to determine the degree of outflow obstruction, cardiac hemodynamics, the anatomy and diastolic characteristics of the left ventricle, and the coronary anatomy)   
  • Electrophysiologic studies

See Workup for more detail.


Pharmacologic therapy for HCM may include the following:

  • Beta blockers
  • Calcium channel blockers
  • Diltiazem, amiodarone, and disopyramide (rarely)
  • Antitussives to prevent coughing

The following caveats are warranted:

  • Avoid inotropic drugs if possible
  • Avoid nitrates and sympathomimetic amines, except in concomitant coronary artery disease
  • Avoid digitalis
  • Use diuretics with caution

Surgical and catheter-based therapeutic options include the following:

  • Left ventricular myomectomy
  • Mitral valve replacement
  • Permanent pacemaker implantation
  • Catheter septal ablation
  • Placement of an implantable cardioverter defibrillator
  • Heart transplantation

See Treatment and Medication for more detail.



Hypertrophic cardiomyopathy (HCM) is a genetic disorder that is typically inherited in an autosomal dominant fashion with variable penetrance and variable expressivity. The disease has complex symptomatology and potentially devastating consequences for patients and their families.[1] (See Etiology and Prognosis.)

The disorder has a variable presentation and carries a high incidence of sudden death. In fact, HCM is the leading cause of sudden cardiac death in preadolescent and adolescent children. The hallmark of the disorder is myocardial hypertrophy that is inappropriate, often asymmetrical, and occurs in the absence of an obvious inciting hypertrophy stimulus. This hypertrophy can occur in any region of the left ventricle but frequently involves the interventricular septum, which results in an obstruction of flow through the left ventricular (LV) outflow tract. (See Prognosis, History, Physical Examination, and Workup.)

Decades ago, HCM was written about and known as idiopathic hypertrophic subaortic stenosis (IHSS) or asymmetrical septal hypertrophy (ASH). These terms were replaced by hypertrophic cardiomyopathy, because the segmental hypertrophy can occur in any segment of the ventricle, not just the septum. Furthermore, this entity can present without subaortic obstruction to flow yet still carry the same ominous risk of arrhythmogenic sudden death and many of its clinical symptoms.

HCM can be separated into obstructive and nonobstructive types. Obstructive HCM is due to midsystolic obstruction of flow through the LV outflow tract as a result of a Bernoulli effect–induced systolic anterior mitral valve movement toward the septum.

The significance of this obstruction, however, is highly controversial. Some investigators and experts believe the obstruction has less to do with the overall hemodynamic and pathophysiologic manifestations of this entity than it does with the inappropriate segmental hypertrophy, which, with its increased myocardial oxygen consumption and substrate for fatal ventricular arrhythmias, has much more significance in the overall clinical picture of this entity and in the treatment and prognosis of HCM.

HCM is a familial disease.[2] There are defects in several of the genes encoding for the sarcomeric proteins, such as myosin heavy chain, actin, tropomyosin, and titin.[3, 4] Multiple mutations have been identified, with genotype-specific risks for mortality and degree of hypertrophy. Interestingly, the genetic basis of ventricular hypertrophy does not directly correlate with prognostic risk stratification. (See Etiology.)

Patients with some mutations, such as specific tropomyosin substitutions, have only a mild degree of ventricular hypertrophy, with little or no LV outflow tract obstruction, but they still carry a disproportionately high risk for sudden death.[5]

Many patients, particularly children, with HCM may not be symptomatic. Careful evaluation of a heart murmur may reveal the condition. (See Physical Examination and Workup.)


Complications of HCM may include the following:

  • Congestive heart failure
  • Ventricular and supraventricular arrhythmias
  • Infective mitral endocarditis
  • Atrial fibrillation with mural thrombus formation
  • Sudden death


Since the initial descriptions of hypertrophic cardiomyopathy (HCM), the feature that has attracted the greatest attention is the dynamic pressure gradient across the LV outflow tract. The pressure gradient appears to be related to further narrowing of an already small outflow tract (already narrowed by the marked asymmetrical septal hypertrophy and possibly by an abnormal location of the mitral valve) by the systolic anterior motion of the mitral valve against the hypertrophied septum.

Three explanations for the systolic anterior motion of the mitral valve have been offered, as follows: (1) the mitral valve is pulled against the septum by contraction of the papillary muscles, which occurs because of the valve's abnormal location and septal hypertrophy altering the orientation of the papillary muscles; (2) the mitral valve is pushed against the septum because of its abnormal position in the outflow tract; (3) the mitral valve is drawn toward the septum because of the lower pressure that occurs as blood is ejected at high velocity through a narrowed outflow tract (Venturi effect).

Most patients with HCM have abnormal diastolic function (whether or not a pressure gradient is present), which impairs ventricular filling and increases filling pressure, despite a normal or small ventricular cavity. These patients have abnormal calcium kinetics and subendocardial ischemia, which are related to the profound hypertrophy and myopathic process.



Abnormal calcium kinetics

Data link abnormal myocardial calcium kinetics to the cause of the inappropriate myocardial hypertrophy and specific features of HCM, particularly in patients with diastolic functional abnormalities. Abnormal myocardial calcium kinetics and abnormal calcium fluxes from an increase in the number of calcium channels result in an increase in intracellular calcium concentration, which, in turn, may produce hypertrophy and cellular disarray.

Genetic causes

Familial HCM occurs as an autosomal dominant Mendelian-inherited disease in approximately 50% of cases. Some, if not all, of the sporadic forms of the disease may be caused by spontaneous mutations.

At least 6 different genes on at least 4 chromosomes are associated with HCM, with more than 50 different mutations discovered thus far. Familial HCM is a genetically heterogenous disease in that it can be caused by genetic defects at more than 1 locus.

In 1989, Seidman and collaborators first reported the genetic basis for HCM. They reported the existence of a disease gene located on the long arm of chromosome 14. Subsequently, they found this to be the gene encoding for beta cardiac myosin heavy chain.

Wide variation exists in the phenotypic expression of a given mutation of a given gene, with variability in clinical symptoms and the degree of hypertrophy expressed. Phenotypic variability is related to the differences in genotype, with specific mutations associated with particular symptoms, the degree of hypertrophy, and the prognosis.[6]

Other possible causes

Other possible causes of HCM include the following:

  • Abnormal sympathetic stimulation - Heightened responsiveness of the heart to the excessive production of catecholamines or the reduced neuronal uptake of norepinephrine might cause HCM
  • Abnormally thickened intramural coronary arteries - These do not dilate normally, which leads to myocardial ischemia; this progresses to myocardial fibrosis and abnormal compensatory hypertrophy
  • Subendocardial ischemia - This is related to abnormalities of the cardiac microcirculation that deplete the energy stores essential for the sequestration of calcium during diastole; subendocardial ischemia results in persistent interaction of the contractile elements during diastole and increased diastolic stiffness
  • Cardiac structural abnormalities - These include a catenoid configuration of the septum, which results in myocardial cell hypertrophy and disarray


Hypertrophic cardiomyopathy (HCM) is reported in 0.5% of the outpatient population referred for echocardiography.[7] The overall prevalence of HCM is low and has been estimated to occur in 0.05-0.2% of the population.[8] Morphologic evidence of disease is found by echocardiography in approximately 25% of first-degree relatives of patients with HCM. Genetic testing still is in the early stages of research development but can be used to identify asymptomatic family members with the same mutation as the proband (index case).

Sex-related demographics

HCM is slightly more common in males than in females. However, the genetic inheritance pattern is autosomal dominant, without sex predilection. Modifying genetic, hormonal, and environmental factors may lead to a higher likelihood of identification in males, increased symptomatology, or higher degrees of LV outflow obstruction, with more prominent findings upon physical examination.

HCM usually presents at a younger age in females. Females tend to be more symptomatic and are more likely to be disabled by their symptoms than males.

Age-related demographics

In general, HCM has a bimodal peak of occurrence. The most common presentation is in the third decade of life, but it may present in persons of any age, from newborns to elderly individuals.

In children, inherited cases are found in an age range from newborn (ie, stillborn babies) to adult. The peak incidence is in these cases is in the second decade of life.

In adults, the peak incidence is in the third decade of life, with the vast majority of cases occurring in the age range between the third and sixth decades of life.



Reported annual mortality rates in patients with hypertrophic cardiomyopathy (HCM) have ranged from less than 1% to 3-6%, and studies suggest that they have significantly improved over the past 40 years.[9]

A 2006 study reported that published sudden death rates over the previous 10 years were lower than were previously published figures (median 1.0% (range 0.1–1.7) v 2.0% (0–3.5)). Nevertheless, HCM still carries a high risk for mortality and morbidity.[10]

One series of 46 patients with midventricular obstruction was found to have an increased risk of apical aneurysm formation, symptoms, and HCM-related death compared with those who did not have midventricular obstruction; the increased risk of symptoms and death was similar to that seen in patients with LV outflow obstruction.[11]

Most patients with HCM are asymptomatic. Unfortunately, the first clinical manifestation of the disease in such individuals may be sudden death, likely from ventricular tachycardia or fibrillation. Younger patients, particularly children, have a much higher mortality rate. Children have a much greater degree of ventricular hypertrophy and are much more symptomatic early on in the disease course, most likely because more malignant genotypes are present earlier in life.

The more benign mutations do not elicit a clinical or echocardiographic phenotype or symptoms in the pediatric population. Death often is sudden, unexpected, and typically is associated with sports or vigorous exertion. Early diagnosis is of prime importance in order to prescribe an appropriate level of safe activity.[6, 12, 13]

Screening of first-degree relatives is useful to identify additional affected family members prior to the onset of significant symptoms or sudden death.

Patients can have a myriad of arrhythmias, including atrial fibrillation, atrial flutter, ventricular ectopy, ventricular tachycardia, and ventricular fibrillation. These patients are among the highest-risk group for ventricular fibrillation and pose difficult therapeutic decisions for risk reduction.

Patients have a high likelihood of recurrent heart failure resulting from mitral regurgitation and profound diastolic dysfunction. HCM is a progressive condition that worsens over time, as does the gradient across the LV outflow tract if left untreated. Systolic function usually is well preserved until the late stages of the disease. Angina is rare in children but common in adults. Syncope and presyncope are common and may identify individuals at high risk for sudden death.


Patient Education

Family members should learn cardiopulmonary resuscitation. In addition, refer the patient and family for psychosocial counseling. Refer children of patients with hypertrophic cardiomyopathy (HCM), especially those in the pediatric age range, for urgent echocardiography and genetic testing if an echocardiogram does not yet reveal overt disease.

Impose activity restrictions that include total abstinence from highly competitive athletic activities and very strenuous physical exertion, such as lifting heavy objects, lifting weights, and shoveling snow.

For patient education information, see the Heart Health Center, as well as Palpitations.

Contributor Information and Disclosures

Sandy N Shah, DO, MBA, FACC, FACP, FACOI Cardiologist

Sandy N Shah, DO, MBA, FACC, FACP, FACOI is a member of the following medical societies: American College of Cardiology, American College of Osteopathic Internists, American College of Physicians, American Osteopathic Association, Society for Cardiovascular Angiography and Interventions, American Society of Nuclear Cardiology, American Medical Association

Disclosure: Nothing to disclose.

Chief Editor

Henry H Ooi, MD, MRCPI Director, Advanced Heart Failure and Cardiac Transplant Program, Nashville Veterans Affairs Medical Center; Assistant Professor of Medicine, Vanderbilt University School of Medicine

Disclosure: Nothing to disclose.


Gary Edward Sander, MD, PhD, FACC, FAHA, FACP, FASH Professor of Medicine, Director of CME Programs, Team Leader, Root Cause Analysis, Tulane University Heart and Vascular Institute; Director of In-Patient Cardiology, Tulane Service, University Hospital; Visiting Physician, Medical Center of Louisiana at New Orleans; Faculty, Pennington Biomedical Research Institute, Louisiana State University; Professor, Tulane University School of Medicine

Gary Edward Sander, MD, PhD, FACC, FAHA, FACP, FASH is a member of the following medical societies: Alpha Omega Alpha, American Chemical Society, American College of Cardiology, American College of Chest Physicians, American College of Physicians, American Federation for Clinical Research, American Federation for Medical Research, American Heart Association, American Society for Pharmacology and Experimental Therapeutics, American Society of Hypertension,American Thoracic Society, Heart Failure Society of America, Louisiana State Medical Society, National Lipid Association, and Southern Society for Clinical Investigation

Disclosure: Forest Labs Honoraria Speaking and teaching

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

  1. Ly HQ, Greiss I, Talakic M, et al. Sudden death and hypertrophic cardiomyopathy: a review. Can J Cardiol. 2005 Apr. 21(5):441-8. [Medline].

  2. Colombo MG, Botto N, Vittorini S, Paradossi U, Andreassi MG. Clinical utility of genetic tests for inherited hypertrophic and dilated cardiomyopathies. Cardiovasc Ultrasound. 2008 Dec 19. 6:62. [Medline]. [Full Text].

  3. Morimoto S. Sarcomeric proteins and inherited cardiomyopathies. Cardiovasc Res. 2008 Mar 1. 77(4):659-66. [Medline].

  4. Soor GS, Luk A, Ahn E, Abraham JR, Woo A, Ralph-Edwards A, et al. Hypertrophic cardiomyopathy: current understanding and treatment objectives. J Clin Pathol. 2009 Mar. 62(3):226-35. [Medline].

  5. Van Driest SL, Ackerman MJ, Ommen SR, Shakur R, Will ML, Nishimura RA, et al. Prevalence and severity of "benign" mutations in the beta-myosin heavy chain, cardiac troponin T, and alpha-tropomyosin genes in hypertrophic cardiomyopathy. Circulation. 2002 Dec 10. 106(24):3085-90. [Medline].

  6. [Guideline] Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2003 Nov 5. 42(9):1687-713. [Medline].

  7. Maron BJ, Peterson EE, Maron MS, Peterson JE. Prevalence of hypertrophic cardiomyopathy in an outpatient population referred for echocardiographic study. Am J Cardiol. 1994 Mar 15. 73(8):577-80. [Medline].

  8. Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation. 1995 Aug 15. 92(4):785-9. [Medline].

  9. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002 Mar 13. 287(10):1308-20. [Medline].

  10. Elliott PM, Gimeno JR, Thaman R, Shah J, Ward D, Dickie S, et al. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart. 2006 Jun. 92(6):785-91. [Medline].

  11. Minami Y, Kajimoto K, Terajima Y, et al. Clinical implications of midventricular obstruction in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2011 Jun 7. 57(23):2346-55. [Medline].

  12. DeRose JJ Jr, Banas JS Jr, Winters SL. Current perspectives on sudden cardiac death in hypertrophic cardiomyopathy. Prog Cardiovasc Dis. 1994 May-Jun. 36(6):475-84. [Medline].

  13. Maron BJ, Roberts WC, Epstein SE. Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients. Circulation. 1982 Jun. 65(7):1388-94. [Medline].

  14. [Guideline] Elliott PM, Anastasakis A, Borger MA, et al, for the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J. 2014 Oct 14. 35 (39):2733-79. [Medline].

  15. Musat D, Sherrid MV. Echocardiography in the treatment of hypertrophic cardiomyopathy. Anadolu Kardiyol Derg. 2006 Dec. 6 Suppl 2:18-26. [Medline].

  16. Peteiro J, Bouzas-Mosquera A, Fernandez X, et al. Prognostic value of exercise echocardiography in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 2012 Feb. 25(2):182-9. [Medline].

  17. Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010 Sep 7. 56(11):875-87. [Medline].

  18. Soor GS, Luk A, Ahn E, Abraham JR, Woo A, Ralph-Edwards A, et al. Hypertrophic cardiomyopathy: current understanding and treatment objectives. J Clin Pathol. 2009 Mar. 62(3):226-35. [Medline].

  19. Verlinden NJ, Coons JC. Disopyramide for hypertrophic cardiomyopathy: a pragmatic reappraisal of an old drug. Pharmacotherapy. 2015 Dec. 35 (12):1164-72. [Medline].

  20. Boggs W. Stepwise antihypertensive therapy effective in hypertrophic cardiomyopathy. Medscape Medical News. February 4, 2013. Available at Accessed: February 26, 2013.

  21. Argulian E, Messerli FH, Aziz EF, Winson G, Agarwal V, Kaddaha F, et al. Antihypertensive Therapy in Hypertrophic Cardiomyopathy. Am J Cardiol. 2013 Jan 19. [Medline].

  22. [Guideline] Gersh BJ, Maron BJ, Bonow RO, et al, for the ACCF/AHA, AATS, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011 Dec 13. 124 (24):2761-96. [Medline].

  23. [Guideline] Gersh BJ, Maron BJ, Bonow RO, et al, for the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Tho... J Am Coll Cardiol. 2011 Dec 13. 58 (25):e212-60. [Medline].

  24. Elliott PM, Anastasakis A, Borger MA, et al, for the European Society of Cardiology Task Force members,. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014 Oct 14. 35 (39):2733-79. [Medline].

  25. Gillinov AM. Updated guidelines for device-based therapy of cardiac rhythm abnormalities. J Thorac Cardiovasc Surg. 2012 Dec. 144 (6):1285. [Medline].

  26. Schaff HV, Dearani JA, Ommen SR, Sorajja P, Nishimura RA. Expanding the indications for septal myectomy in patients with hypertrophic cardiomyopathy: Results of operation in patients with latent obstruction. J Thorac Cardiovasc Surg. 2012 Feb. 143(2):303-9. [Medline].

  27. Panaich SS, Badheka AO, Chothani A, et al. Results of ventricular septal myectomy and hypertrophic cardiomyopathy (from Nationwide Inpatient Sample [1998-2010]). Am J Cardiol. 2014 Nov 1. 114 (9):1390-5. [Medline].

  28. Vriesendorp PA, Schinkel AF, Soliman OI, et al. Long-term benefit of myectomy and anterior mitral leaflet extension in obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2015 Mar 1. 115 (5):670-5. [Medline].

  29. Singh K, Qutub M, Carson K, Hibbert B, Glover C. A meta analysis of current status of alcohol septal ablation and surgical myectomy for obstructive hypertrophic cardiomyopathy. Catheter Cardiovasc Interv. 2015 Nov 3. [Medline].

  30. Qintar M, Morad A, Alhawasli H, et al. Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy. Cochrane Database Syst Rev. 2012 May 16. 5:CD008523. [Medline].

  31. Hagège AA, Desnos M. New trends in treatment of hypertrophic cardiomyopathy. Arch Cardiovasc Dis. 2009 May. 102(5):441-7. [Medline].

  32. Jassal DS; Neilan TG; Fifer MA; Palacios IF; Lowry PA; Vlahakes GJ; Picard MH; Yoerger DM, Cardiac Ultrasound Laboratory, Cardiology Division, Massachusetts General Hospital, Boston, MA 02114, et al. Sustained improvement in left ventricular diastolic function after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Eur Heart J. 2006; 27(15):1805-10 (ISSN: 0195-668X).

  33. Streit S, Walpoth N, Windecker S, Meier B, Hess O. Is alcohol ablation of the septum associated with recurrent tachyarrhythmias?. Swiss Med Wkly. 2007 Dec 1. 137(47-48):660-8. [Medline].

  34. Lin G, Nishimura RA, Gersh BJ, et al. Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy. Heart. 2009 May. 95 (9):709-14. [Medline].

  35. Pillarisetti J, Kondur A, Alani A, et al. Peripartum cardiomyopathy: predictors of recovery and current state of implantable cardioverter-defibrillator use. J Am Coll Cardiol. 2014 Jul 1. 63 (25 Pt A):2831-9. [Medline].

  36. Ashikhmina E, Farber MK, Mizuguchi KA. Parturients with hypertrophic cardiomyopathy: case series and review of pregnancy outcomes and anesthetic management of labor and delivery. Int J Obstet Anesth. 2015 Nov. 24 (4):344-55. [Medline].

  37. [Guideline] Federal Motor Carrier Safety Administration (FMCSA). Recommendations of the medical expert panel. (See section 9: CMV drivers with cardiomyopathy). Available at Updated August 28, 2015; Accessed: December 22, 2015.

  38. Federal Aviation Administration. Guide for aviation medical examiners. Decision considerations - aerospace medical dispositions. Item 36. Heart. Available at Modified June 20, 2014; Accessed: December 22, 2015.

  39. Maron BJ, Barry JA, Poole RS. Pilots, hypertrophic cardiomyopathy, and issues of aviation and public safety. Am J Cardiol. 2004 Feb 15. 93 (4):441-4. [Medline].

  40. Pack C. Hypertrophic cardiomyopathy in a first-class airman. The Federal Air Surgeon's Medical Bulletin. Vol 51, no 2. Revised April 29, 2013. Accessed December 22, 2015. Available at

  41. Federal Aviation Administration. Guide for aviation medical examiners. Decision considerations - aerospace medical dispositions. Item 36. Heart - other cardiac conditions. Available at Modified June 20, 2014; Accessed: December 22, 2015.

  42. Maron BJ, Isner JM, McKenna WJ. 26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 3: hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse. J Am Coll Cardiol. 1994 Oct. 24(4):880-5. [Medline].

  43. Thompson PD, Franklin BA, Balady GJ, Blair SN, Corrado D, Estes NA 3rd, et al. Exercise and acute cardiovascular events placing the risks into perspective: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism and the Council on Clinical Cardiology. Circulation. 2007 May 1. 115(17):2358-68. [Medline].

  44. Counihan PJ, McKenna WJ. Low-dose amiodarone for the treatment of arrhythmias in hypertrophic cardiomyopathy. J Clin Pharmacol. 1989 May. 29(5):436-8. [Medline].

  45. Fananapazir L, Leon MB, Bonow RO, et al. Sudden death during empiric amiodarone therapy in symptomatic hypertrophic cardiomyopathy. Am J Cardiol. 1991 Jan 15. 67(2):169-74. [Medline].

  46. [Guideline] Epstein AE, Dimarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS, et al. ACC/AHA/HRS 2008 guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: executive summary. Heart Rhythm. 2008 Jun. 5(6):934-55. [Medline].

  47. Topilski I; Sherez J; Keren G; Copperman I, Department of Cardiology, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel. Long-term effects of dual-chamber pacing with periodic echocardiographic evaluation of optimal atrioventricular delay in patients with hypertrophic cardiomyopathy >50 years of age. Am J Cardiol. 2006. 97(12):1769-1775.

  48. Galve E, Sambola A, Saldaña G, Quispe I, Nieto E, Diaz A, et al. Late benefits of dual-chamber pacing in obstructive hypertrophic cardiomyopathy. A 10-year follow-up study. Heart. 2009 May 28. [Medline].

  49. Silva LA, Fernández EA, Martinelli Filho M, Costa R, Siqueira S, Ianni BM, et al. Cardiac pacing in hypertrophic cardiomyopathy: a cohort with 24 years of follow-up. Arq Bras Cardiol. 2008 Oct. 91(4):250-6, 274-80. [Medline].

  50. You JJ, Woo A, Ko DT, Cameron DA, Mihailovic A, Krahn M. Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy. Am Heart J. 2007 Nov. 154(5):899-907. [Medline].

  51. Jensen MK, Prinz C, Horstkotte D, van Buuren F, Bitter T, Faber L, et al. Alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy: low incidence of sudden cardiac death and reduced risk profile. Heart. 2013 Jul. 99(14):1012-7. [Medline].

  52. McKinney AM, Lohman BD, Sarikaya B, Benson M, Benson MT, Lee MS. Accuracy of routine fat-suppressed FLAIR and diffusion-weighted images in detecting clinically evident optic neuritis. Acta Radiol. 2013 Feb 5. [Medline].

  53. Tracy CM, Epstein AE, Darbar D, et al, for the American College of Cardiology Foundation, American Heart Association Task Force on Practice Guidelines, et al. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. [corrected]. Circulation. 2012 Oct 2. 126 (14):1784-800. [Medline].

  54. Zhao DS, Shen Y, Zhang Q, et al. Outcomes of catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: a systematic review and meta-analysis. Europace. 2015 Nov 26. [Medline].

All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.